PCSK9 and cancer: A paired T-test performed between women with a benign pathology of the breast and age-matched stage III cancer subgroup indicated a significant increase in PCSK9 concentrations in the stage III cancer subgroup (95.9 ± 27.1 ng/mL) compared to women in the benign group (78.5 ± 19.3 ng/mL), as shown in Fig. 3B (p-value = 0.031, n = 14 in each group).